In Phase 2b development for the treatment of life-threatening fungal infections First antifungal agent to receive Breakthrough Therapy designation MANCHESTER, UK / VIENNA, Austria – November 11, 2019 – F2G Ltd, … Continue reading “F2G Receives US FDA Breakthrough Therapy Designation for Olorofim”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present scientific posters at the following conferences in … Continue reading “IXICO to Present Abstracts at Upcoming Huntington’s Disease and Ataxia Conferences”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October … Continue reading “IXICO to Present at 10th Annual CNS Summit 2019”
Masters Speciality Pharma, a UK-headquartered pharmaceutical company specialising in the global distribution of high-quality, life-changing medicines, today announces the recent launch in Brazil of Neuropad®, a rapid and reliable screening … Continue reading “Masters Speciality Pharma Announces Launch of Neuropad® in Brazil for Detection of Diabetic Foot Syndrome”
-Neuraxpharm establishes Swiss footprint with acquisition of leading cannabidiol company -S.T.U. GmbH is the owner of market leading brand Hemplix™ October 29, 2019 Neuraxpharm Group (Neuraxpharm), a leading European specialty … Continue reading “Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces three new biopharma contracts and the appointment of Lammert Albers as Chief Business Officer effective … Continue reading “IXICO announces client contracts and appointment of Chief Business Officer”
Amsterdam, The Netherlands, 22 October 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces the formation of … Continue reading “Kiadis Pharma announces formation of renowned Scientific Advisory Board”
Results to Inform Development Plan and Dose Selection for Phase 3 LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company … Continue reading “Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD”
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, is pleased to announce a trading update for the year ended 30 September 2019. IXICO is expecting … Continue reading “IXICO Company reports fast tracked achievement of initial year positive EBITDA, 40% revenue growth and strong cash position”
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom … Continue reading “Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019”
ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited … Continue reading “ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology”
The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type … Continue reading “ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank”
• Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. • The two companies will leverage their combined scientific, commercial and market access expertise to … Continue reading “GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer”
Castor establishes new US operations, building on leadership position across the EU Amsterdam, The Netherlands and Hoboken, New Jersey, USA, October 7, 2019: Castor, a health-tech company that helps medical … Continue reading “Castor Announces International Expansion to Meet Growing Demand for an AI-Powered Clinical Data Platform”
Novel deep-learning approach for predicting and explaining the key prognostic factors for patients with Mesothelioma Paris, France and New York, USA, October 7th, 2019 – Owkin, which is developing machine … Continue reading “Owkin publishes breakthrough research in Nature Medicine”
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, … Continue reading “Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon”
Further strengthens position in oncology; investment in STipe increases oncology portfolio to six companies Dr Christian Schetter, Entrepreneur in Residence at Arix Bioscience, joins STipe as Executive Chairman LONDON, 30 … Continue reading “Arix co-leads EUR 20 million Series A investment round for STipe Therapeutics”
Date September 30, 2019 Location Copenhagen STipe funded through Novo Seeds’ company building efforts First company out of BioInnovation Institute, a new Novo Nordisk Foundation initiative Novo Seeds, the company … Continue reading “Novo Seeds co-leads €20 Million Series A Financing in STipe Therapeutics”
OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment Beerse, Belgium, 25 September 2019 – … Continue reading “OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com